Inhibitor Therapeutics (INTI) Research & Development (2013 - 2026)
Inhibitor Therapeutics' (INTI) quarterly Research & Development came in at $340562.0 in Q1 2026, up 44.27% YoY from $236058.0 in Q1 2025, and down 55.03% on a QoQ basis from $757248.0 in Q4 2025.
Inhibitor Therapeutics (INTI) Research & Development (2013 - 2026) Analysis & Trends
Inhibitor Therapeutics (INTI) has 14 years of Research & Development data on file, last reported at $340562.0 in Q1 2026.
- Quarterly Research & Development rose 44.27% year-over-year to $340562.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.8 million (up 3.92% YoY) and the FY2025 annual result came in at $1.7 million, down 3.46% from the prior year.
- Research & Development retreated to $340562.0 in Q1 2026, from $757248.0 in the prior quarter.
- In the past five years, Research & Development ranged from a high of $887794.0 in Q4 2024 to a low of $6150.0 in Q2 2022.
- A 5-year average of $370146.1 and a median of $293194.0 in 2023 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2023 — Research & Development soared 3704.76% — and 2025, when it declined 14.7%.
- Tracing INTI's Research & Development over 5 years: stood at $6150.0 in 2022, then jumped by 11036.75% to $684910.0 in 2023, then grew by 29.62% to $887794.0 in 2024, then decreased by 14.7% to $757248.0 in 2025, then slumped by 55.03% to $340562.0 in 2026.
- The last three Research & Development figures came in at $340562.0 (Q1 2026), $757248.0 (Q4 2025), and $377789.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 413.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -588.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 210.03 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 97.90 Mn |
| 10 | Inhibitor Therapeutics | 15.64 Mn | 15.64 Mn | - | 223,564.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 340,562.00 |
| Dec 31, 2025 | 757,248.00 |
| Sep 30, 2025 | 377,789.00 |
| Jun 30, 2025 | 325,623.00 |
| Mar 31, 2025 | 236,058.00 |
| Dec 31, 2024 | 887,794.00 |
| Sep 30, 2024 | 369,621.00 |
| Jun 30, 2024 | 239,776.00 |
| Mar 31, 2024 | 260,359.00 |
| Dec 31, 2023 | 684,910.00 |
| Sep 30, 2023 | 260,765.00 |
| Jun 30, 2023 | 233,993.00 |
| Mar 31, 2023 | 201,398.00 |
| Jun 30, 2022 | 6,150.00 |
| Dec 31, 2021 | 75.00 |
| Jun 30, 2021 | 950.00 |
| Mar 31, 2021 | 3,880.00 |
| Dec 31, 2020 | 2,710.00 |
| Sep 30, 2020 | 32,468.00 |
| Jun 30, 2020 | 52,661.00 |